Back

Brain and Spine Tumor Center

Specialty Cancer Centers

New Patient Appointment

321.841.7218

Active Clinical Trials

  • The treating physician/investigator contacts Lilly when, based on

    To provide abemaciclib to eligible patients with recurrent, locally advanced, unresectable or metastatic breast cancer prior to commercial availability.

  • Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma

    To determine whether the addition of pp65-LAMP mRNA DC vaccine plus GM-CSF and Td to dose-intensified TMZ treatment is worthy of investigation in a large phase III study based on impact on overall survival. Secondary Objectives Evaluate the impact of CMV pp65-LAMP RNA-pulsed DC vaccines on progression-free survival in patients with newly-diagnosed GBM. Determine the immunologic effects of vaccination with pp65 RNA fusion constructs incorporating full-length LAMP vs short LAMP sequences.

  • Cediranib Maleate and Olaparib or Standard Chemotherapy in Treati

    To assess the efficacy and identify (in)active arm(s) of the combination of cediranib (cediranib maleate) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by progression-free survival (PFS) in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess the efficacy of the combination of cediranib and olaparib, and active monotherapy experimental arm(s) from Randomized Phase II, as measured by overall survival (OS) and PFS, as compared to physician's choice standard of care chemotherapy in women with recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III) To assess the efficacy of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by objective response rate (ORR: partial or complete response) by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess safety endpoints, as measured by frequency and severity of adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v).4.0. (Phase II and Phase III) III. To assess the efficacy of the combination of cediranib and olaparib, and active monotherapy experimental arm(s) from Randomized Phase II, as measured by ORR, as compared to physician's choice standard of care chemotherapy in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

  • Pre-Test Genetic Education and Remote Genetic Counseling in Commu

    PRIMARY OBJECTIVES: I. To evaluate the efficacy of web-based pre-test genetic education (i.e. before receipt of tumor profile results) to increase knowledge (genetic knowledge and knowledge of test benefits and limitations). (Step 1) II. To evaluate the efficacy of web-based pre-test genetic education (i.e. before receipt of tumor profile results) to decrease distress (anxiety, depression and cancer specific worry) compared to usual care services in patients undergoing tumor profiling for advanced cancer. (Step 1) III. To evaluate the uptake of remote genetic counseling (Step 2) IV. To evaluate the uptake of germline testing among advanced cancer patients with a potential clinically significant incidental germline mutation identified through tumor profiling in the Molecular Analysis for Therapy Choice (MATCH) trial. (Step 2) SECONDARY OBJECTIVES: I. To evaluate potential moderators suggested by the self-regulation theory of health behavior (SRTHB) (e.g. test result, sociodemographic factors, health literacy, baseline knowledge or distress) to changes in knowledge of genetic disease and test benefits and limitations. (Step 1) II. To evaluate potential moderators suggested by the SRTHB (e.g test result, sociodemographic factors, health literacy, baseline knowledge or distress) to changes in distress in patients undergoing tumor profiling for advanced cancer. (Step 1) III. To evaluate factors associated with uptake of genetic counseling and germline testing. (Step 2) IV. To evaluate cognitive, affective and behavioral (communication to relatives) responses to confirmatory germline testing in advanced cancer patients with potential clinically significant incidental germline mutation identified in tumor profiling. (Step 2)

  • A Study of Rucaparib Verses Physician's Choice of Therapy in Pati

    The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib verses treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

  • Blinatumomab and Combination Chemotherapy or Dasatinib, Prednison

    This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Monoclonal antibodies, such as blinatumomab, find cancer cells and help kill them. Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.

  • Pembrolizumab in Treating Patients With Triple-Negative Breast Ca

    To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >= 1 cm residual invasive breast cancer and/or positive lymph nodes (> ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PD-L1 positive subset. To compare the effects of MK-3475 (pembrolizumab) on overall survival (OS) and distant recurrence-free survival (DRFS) between the two randomized arms for the PD-L1 positive patients and then all patients. II. To assess the toxicity and tolerability of MK-3475 (pembrolizumab) in this patient population with or without radiation therapy

  • Phase 2 Study of Atezolizumab With or Without Entinostat in Patie

    Phase 1b (Dose Determination Cohort): To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of entinostat (SNDX-275) given in combination with atezolizumab. Phase 2 (Expansion Cohort): To perform an evaluation of the efficacy of entinostat at the RP2D in combination with atezolizumab in patients with aTNBC, as determined by the duration of progression-free survival (PFS) based on the local investigator’s assessment of progressive disease using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) .

  • Phase I dose-escalation study of BAY 1129980

    To determine the safety, tolerability and maximum tolerated dose (MTD) of BAY 1129980. To evaluate the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarkers, and tumor response profile of BAY 1129980

  • RTOG 3504

    Primary Objectives for Phase I Lead In To evaluate the safety of the addition of nivolumab (anti PD-1 immunotherapy) to chemoradiotherapy with weekly cisplatin (40 mg/m2/week x 7) for patients with intermediate or high-risk head and neck squamous cell carcinoma (HNSCC) (Arm 1)To evaluate the safety of the addition of nivolumab (anti PD-1 immunotherapy) to chemoradiotherapy with high-dose cisplatin (100 mg/m2 q 21 days x 3) for patients with intermediate or high-risk head and neck squamous cell carcinoma (HNSCC) (Arm 2); To evaluate the safety of the addition of nivolumab (anti PD-1 immunotherapy) to chemoradiotherapy with weekly cetuximab (400 mg/m2 load, 250 mg/m2/week x 7) for patients with intermediate- or high-riskhead and neck squamous cell carcinoma (HNSCC) (Arm 3); To evaluate the safety of the addition of nivolumab (anti PD-1 immunotherapy) to radiotherapy for patients with intermediate or high-risk head and neck squamous cell carcinoma (HNSCC) with age > 70 years; Zubrod Performance Status 2; baseline grade ≥ 3 neuropathy; grade ≥2 hearing loss; or CrCl < 50 ml/min (Arm 4). Primary Objective for Phase III Trial To compare overall survival (OS) for patients with newly diagnosed, intermediate or high-risk local-regionally advanced HNSCC treated with cisplatin-based CRT with or without nivolumab.